通过β-上腺素受体信号通路介导的s-limonene在老鼠心脏中的抗节律活性
Joyce Francielle Ferreira Santos1, Diego Santos de Souza1, Karina Oliveira Mota1
1Department of Physiology, Federal University of Sergipe, Sao Cristovao, Brazil.
Clinical and experimental pharmacology & physiology
|September 3, 2024
概括
S-Limonene (s-Lim) 通过阻断心脏中的β-上腺素受体 (β-AR) 来表现出抗心律失常的作用. 这项研究揭示了s-Lim
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管生理学心血管生理学
- 自然产品 化学 化学
背景情况:
- S-Limonene (s-Lim) 是一种植物性单烯,具有已知的抗氧化和心脏保护性质.
- 它的潜在抗失常机制,特别是涉及β-上腺素受体 (β-AR) 阻塞,需要详细的研究.
- 了解s-Lim对心脏电生理学和信号通路的影响对于其治疗发展至关重要.
研究的目的:
- 阐明S-Limonene (s-Lim) 的抗心律失常机制.
- 调查s-Lim.对β-上腺受体 (β-AR) 阻断的作用.
- 评估s-Lim对心脏功能和电生理学的体内和体外影响.
主要方法:
- 隔离心脏制剂和心室心肌细胞被用于体外评估.
- 分析了心电图 (ECG) 测量,左心室发达压力 (LVDP) 和离子通道电流 (ICa,L).
- 在体内研究中使用了异二醇 (ISO) 诱导的心律失常模型和咖啡因/ISO挑战.
主要成果:
- 在孤立的心脏中,S-Limonene (s-Lim) 剂量依赖地影响心率和QT间隔.
- s-Lim抑制的异二醇 (ISO) 诱导的心率和LVDP的增加,以及对抗的多布他胺诱导的心肌细胞缩短的增加,类似于β-AR抑制剂.
- s-Lim在体内表现出抗心律失常作用,降低心律失常得分并预防心室心律失常,而不会影响L型电流 (ICa,L) 或腺酸环酶活性.
结论:
- S-Limonene (s-Lim) 的抗失常活性主要归因于对心脏β-腺受体 (β-AR) 的阻断.
- s-Lim在预防实验诱导的心律失常方面表现出有效性.
- 这些发现支持s-Lim作为治疗心律障碍的治疗剂的潜力.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
Adrenergic Antagonists: ɑ and β-Receptor Blockers
421
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
421
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
935
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
935
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
544
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
544
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
835
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
835


